Jubilant Ingrevia · risk themes across the available quarters.
Bear-case history
Vitamin B3 and pyrithione derivative prices experienced trough levels in Q2, impacting nutrition margins. While management expects recovery, pricing remains market-driven and unpredictable, with the next 1-2 quarters critical for confirming stabilization.
Analyst raised concerns about US tariff announcements and India-US tensions. Management acknowledged some CDMO discussions that should have closed in 3 months are now taking 6-8 months due to short-term customer uncertainty, though long-term strategic rationale for India partnerships remains intact.
Despite volume recovery to highest levels in 6 quarters, EBITDA remained stable QoQ as market-driven contribution erosion from lower raw material costs and oversupply continues to impact profitability in ethyl acetate and acetic anhydride.
While management expressed optimism about capturing meaningful share of the 30,000-40,000 ton European choline chloride market following anti-dumping duties, the qualification process takes weeks to months and early Q2 orders were modest relative to business size.
Pricing declines in specialty chemicals (pyridine derivatives), nutrition (B3, choline), and chemical intermediates have offset volume gains. While management sees bottoming, no significant recovery materialized yet in Q3.
European operations face weak demand and plant closures weighing on chemical intermediates segment. Rising raw material costs squeeze margins in oversupplied market.
Large Rs 1,400 crore agrochemical CDMO order commencement was delayed from January to late March 2026; analyst questioned whether customer regulatory tightening or volume commitments could affect Jubilant's visibility—management declined to provide specifics citing confidentiality.
EU FTA benefits (removal of 6-7% duties) contingent on agreement execution in early 2026; customer order patterns remained tentative during uncertainty period, and actual volume/pricing gains dependent on case-by-case negotiations.
One of the key agro CDMO customers is going through tough market conditions. While the company has volume visibility for Q1 and contractual protection for any shortfall, the delayed volume confirmation creates execution uncertainty for FY27 projections.
Acetic acid prices have sharply risen and are now falling. Management indicated it has minimized inventory impact through thoughtful purchasing at peak prices, but acknowledged potential impact could linger into early Q2 if prices continue declining. The pricing environment remains dynamic for the acetys segment.
The $300 million agro CDMO contract was signed when USD/INR was around 84, now at 96. While management stated natural hedging through imports ($500 crore+ exports and similar imports) will limit impact, it acknowledged some positive benefit but not linear with the 12-rupee appreciation.
Management noted pyridine prices are at rock bottom while beta-picoline prices are at multi-year highs. This counter-cyclical behavior balances margins but creates pricing uncertainty for the largest specialty chemicals product line (50,000 MT capacity at 90%+ utilization).